论文信息 - First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) - 字舞流文

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

P. Fournel | F. Guisier | R. Descourt | R. Gervais | R. Veillon | L. Falchero | L. Greillier | M. Pérol | H. Doubre | C. Ricordel | M. Bernardi | C. Decroisette | J. Auliac | G. Justeau | C. Chouaïd | M. Marcq | S. Vieillot | J. Pinsolle | L. Bigay-Gamé | K. Amrane